Story perspectives

DOJ Defends Mifepristone Mail Orders Amid Louisiana Legal Challenge

1/29/2026

Summary

Story summary

The U.S. Department of Justice stated that U.S. Food and Drug Administration regulations permitting the mailing of mifepristone do not violate states' rights to protect the unborn.
Louisiana seeks to block those FDA regulations, arguing they permit illegal abortions.
The U.S. Food and Drug Administration is reviewing mifepristone safety standards, and the U.S. Department of Justice warned that blocking current regulations could disrupt this review.
Critics, including SBA Pro-Life America, condemned the DOJ's stance, arguing that mail-order abortion drugs pose significant risks.
The FDA declined to comment on ongoing litigation.

1 of 1

Story summary

The U.S. Department of Justice stated that U.S. Food and Drug Administration regulations permitting the mailing of mifepristone do not violate states' rights to protect the unborn.
Louisiana seeks to block those FDA regulations, arguing they permit illegal abortions.
The U.S. Food and Drug Administration is reviewing mifepristone safety standards, and the U.S. Department of Justice warned that blocking current regulations could disrupt this review.
Critics, including SBA Pro-Life America, condemned the DOJ's stance, arguing that mail-order abortion drugs pose significant risks.
The FDA declined to comment on ongoing litigation.